成人弥漫性内生性桥脑胶质瘤:96例患者的临床、影像、病理、分子特征及治疗
基于中国脑肿瘤登记处2013年4月至2019年12月数据,纳入96例影像学诊断的成人弥漫性内生性桥脑胶质瘤(DIPG)患者,分析其临床、影像、病理、分子特征及治疗。H3K27M和IDH1突变频率分别为37.2%和26.5%,全组中位总生存期19.5个月,H3K27M突变型预后较IDH突变型及H3K27M阴性/IDH野生型更差。作者建议所有成人DIPG患者进行H3K27M和IDH突变基因组检测。
要点
- 成人DIPG全组中位OS为19.5个月,1年、2年、3年生存率分别为67.0%、42.8%、36.0%。
- H3K27M突变型中位OS为11.4个月,预后较IDH突变型(p<0.001)及H3K27M阴性/IDH野生型(p=0.002)更差。
- H3K27M突变型中接受治疗者中位OS为13.8个月,未接受治疗者为7.5个月(p=0.016)。
核心结论
- 作者建议所有成人DIPG患者进行H3K27M和IDH突变的基因组检测。
- 尽管患病率低,仍需进一步研究以更好地描述各种治疗方式在成人DIPG中的疗效。
研究设计与样本
- 利用中国脑肿瘤登记处(2013年4月至2019年12月)收集影像学诊断的成人DIPG患者数据。
- 共纳入96例成人DIPG患者,分析其临床、影像、病理、分子及治疗特征。
- 采用Kaplan-Meier曲线及单因素、多因素Cox回归进行生存分析。
- 采用卡方检验/Wilcoxon秩和检验及多因素logistic回归分析长期生存(LTS)患者的临床和影像特征。
- 进行了临床因素间的交互作用分析。
主要发现
- 症状出现时中位年龄为33.5岁,中位症状持续时间为4.5个月。
- H3K27M和IDH1突变频率分别为37.2%和26.5%。
- 全组成人中位OS为19.5个月,1年、2年、3年生存率分别为67.0%、42.8%、36.0%。
- 40例未接受治疗患者的中位OS为13.4个月。
- H3K27M突变型中位OS为11.4个月,预后较IDH突变型(p<0.001)及H3K27M阴性/IDH野生型(p=0.002)更差。
关键数值与推荐
- H3K27M突变型中接受治疗者中位OS为13.8个月,未接受治疗者为7.5个月(p=0.016)。
- 在有病理诊断的患者中,H3K27M突变(p<0.001)提示预后更差;在无病理诊断的患者中,MRI增强扫描(p=0.003)提示预后更差。
- 治疗是H3K27M突变型患者的预测因素(p=0.038),MRI增强扫描是H3K27M阴性组的预后因素(p=0.038)。
- H3K27M突变和治疗是症状持续时间≤4个月患者(H3K27M,p=0.020;治疗,p=0.014)及无MRI增强肿瘤患者(H3K27M,p=0.003;治疗,p=0.042)的显著预测因素。
- 长期生存(LTS)患者较少出现颅神经麻痹(p=0.002)和诊断时MRI增强扫描(p=0.022)。
临床怎么用
- 作者建议所有成人DIPG患者进行H3K27M和IDH突变的基因组检测。
- 作者认为尽管患病率低,仍需进一步研究以更好地描述各种治疗方式在成人DIPG中的疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Unlike its pediatric counterpart, adult diffuse intrinsic pontine glioma (DIPG) remains largely unelucidated. In this study, the authors examined the clinical, radiological, pathological, molecular, and clinical aspects of 96 adult DIPGs. METHODS: The National Brain Tumor Registry of China (April 2013-December 2019) was used to collect data on radiologically diagnosed adult DIPG patients. Survival analysis was conducted using Kaplan-Meier curves and univariate and multivariate Cox regression. The chi-square test/Wilcoxon rank-sum test and multivariable logistic regression were used to examine the clinical and radiological characteristics of patients with long-term survival (LTS). Interaction analyses between clinical factors were also conducted. RESULTS: The median age at symptom onset was 33.5 years, and the median duration of symptoms was 4.5 months. The frequencies of H3K27M and IDH1 mutations were 37.2% and 26.5%, respectively. All adult DIPG patients had a median overall survival (OS) of 19.5 months, with 1-, 2-, and 3-year survival rates of 67.0%, 42.8%, and 36.0%, respectively. The median OS of 40 patients who did not undergo treatment was 13.4 months. Patients with H3K27M-mutant tumors had a poorer prognosis than those with IDH-mutant tumors (p < 0.001) and H3K27M(-)/IDH-wild-type tumors (p = 0.002), with a median OS of 11.4 months. The median OSs of patients with H3K27M-mutant tumors who received treatment and those who did not were 13.8 months and 7.5 months, respectively (p = 0.016). Among patients with and without a pathological diagnosis, H3K27M mutation (p < 0.001) and contrast enhancement on MRI (p = 0.003), respectively, imparted a worse prognosis. Treatments were the predictive factor for patients with H3K27M-mutant tumors (p = 0.038), whereas contrast enhancement on MRI was the prognostic factor for the H3K27M(-) group (p = 0.038). In addition, H3K27M mutation and treatment were significant predictors for patients with symptom duration ≤ 4 months (H3K27M, p = 0.020; treatment, p = 0.014) and tumors with no contrast enhancement (H3K27M, p = 0.003; treatment, p = 0.042). Patients with LTS were less likely to have cranial nerve palsy (p = 0.002) and contrast enhancement on MRI at diagnosis (p = 0.022). CONCLUSIONS: It is recommended that all adult DIPG patients undergo genomic testing for H3K27M and IDH mutations. Despite the low prevalence, additional study is needed to better characterize the efficacy of various treatment modalities in adults with DIPG.
引用
- Wang Y, Pan C, Xie M, et al. Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients. J Neurosurg. 2022. PMID: 35395636. doi:10.3171/2022.2.JNS211920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。